Overview
CN Bio is a world-leading provider of organ-on-chip microphysiological systems (MPS) that accelerate drug discovery and development. Their PhysioMimix platform enables pharmaceutical companies to recreate human organs and tissues in vitro for drug efficacy, safety, and ADME profiling before clinical trials. By offering both single and multi-organ capabilities with reliable microfluidics and computational modeling tools, CN Bio reduces development time and costs while improving predictive accuracy compared to traditional cell culture and animal models.
Frequently asked questions
- What are organ-on-chip systems and how do they benefit drug discovery?
- Organ-on-chip systems are microphysiological systems that recreate three-dimensional human organs and tissues in the laboratory. They provide more accurate prediction of drug efficacy and safety than traditional cell culture, while reducing the need for expensive animal and human clinical trials, thereby accelerating time-to-market and lowering development costs.
- What specific applications does CN Bio's PhysioMimix platform support?
- CN Bio's PhysioMimix platform supports drug efficacy assessment, safety profiling, ADME (Absorption, Distribution, Metabolism, and Excretion) analysis, disease modeling, and multi-organ integration. The platform includes organ-specific consumables and can recreate both healthy physiology and complex human disorders for comprehensive drug evaluation.
- Does CN Bio offer contract research services?
- Yes, CN Bio provides Contract Research Services (CRS) that include ADME profiling enhanced with computational modeling capabilities through their PhysioMimix tools, enabling accelerated bioavailability profiling and drug metabolism assessment for pharmaceutical clients.